Amneal to Acquire Kashiv BioSciences; Q1 Beats, Lifts 2026 Outlook

Amneal Pharmaceuticals announced it has entered into a definitive agreement to acquire 100% of Kashiv BioSciences in a transaction that includes $375 million in cash and $375 million in equity payable at closing, with additional contingent regulatory milestone payments and potential royalties.

The deal is structured as a membership interest purchase and contemplates the issuance of 28,942,108 shares of Amneal Class A common stock as part of the equity consideration; the agreement also provides for up to $350 million of milestone-based payments and customary purchase price adjustments related to working capital and transaction mechanics. The Amneal board has approved the transaction, and the companies point to a long-standing commercial relationship as rationale for the combination.

Alongside the acquisition announcement Amneal reported preliminary first-quarter 2026 results and raised its standalone full-year 2026 guidance, citing improving revenue and adjusted EBITDA trends. Company materials present stronger near-term profitability metrics and management highlighted biosimilars as a growth and margin-accretive vector for the business.

Market reaction to the announcement showed investor interest in Amneal shares, with financial news services reporting a move higher in pre-market trading as the strategic rationale—scale in biosimilars and access to Kashiv’s development portfolio—was digested. Analysts note the transaction positions Amneal to pursue a larger share of the global biologics loss-of-exclusivity opportunity while acknowledging near-term integration risks.

Strategically, the acquisition accelerates Amneal’s diversification from core generics into higher-margin branded and biosimilar medicines, complementing recent product launches and pipeline milestones. The deal remains subject to customary closing conditions, shareholder approvals and regulatory clearances, with the company targeting closing in the second half of 2026.

Analyst commentary emphasizes that while the transaction uses a mix of cash and equity which dilutes near-term per-share metrics, successful regulatory filings and commercial launches of Kashiv-originated biosimilars could materially improve Amneal’s revenue mix and adjusted EPS trajectory in 2027–2028. Investors will monitor integration updates, milestone progress and whether the company sustains the upgraded 2026 guidance.